Peer-reviewed veterinary case report
Treatment outcomes for high-risk mast cell tumors in dogs
By Miller, R L et al.·Published in Veterinary and comparative oncology·2016·Dick White Referrals, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A retrospective review of treatment and response of high-risk mast cell tumours in dogs.
- Species:
- dog
Plain-English summary
A group of 94 dogs with high-risk mast cell tumors (a type of skin cancer) were treated to see which methods helped them survive longer. Those who had their tumors surgically removed and received chemotherapy lived significantly longer, averaging about 278 days, compared to those who only received chemotherapy, who averaged 91 days. For dogs with a specific type of tumor that had not spread, treatment with vinblastine and prednisolone led to an impressive average survival of nearly 1,947 days, while those treated with another medication, masitinib, averaged 369 days. This suggests that surgery combined with chemotherapy can greatly improve survival in dogs with these tumors.
People also search for: dog mast cell tumor treatment · mast cell tumor surgery survival · chemotherapy for dog skin cancer
Abstract
This retrospective case series evaluates survival outcome of 94 dogs with high metastatic risk mast cell tumours (MCT). Patients were treated with a cytotoxic chemotherapy protocol or the tyrosine kinase inhibitor masitinib, in the presence of gross disease or as an adjunct to surgical resection of the primary tumour. In patients presenting with metastatic disease, surgical resection of the primary tumour with adjunctive therapy with any chemotherapy incurred a significant survival advantage [median survival time (MST): 278 days] compared to patients receiving chemotherapy without surgical excision of the primary tumour (MST: 91 days, P < 0.0001). Patients with a surgically excised Patnaik grade II tumour and high Ki-67 in the absence of metastatic disease treated with vinblastine and prednisolone showed a significantly longer survival (MST: 1946 days) than those treated with masitinib (MST: 369 days, P = 0.0037). Further prospective case-controlled clinical trials of high-risk MCTs are required to make precise evidence-based treatment decisions for individual patients.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/25223579/